Fosamax and Osteonecrosis of the Jaw: Causation, Risk, and What Studies Show

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Education to Targeted Risk Assessment

The legacy of general health and science information dissemination has long served as a foundation for public understanding of medical conditions and treatments. Within this broad context, community health resources have traditionally focused on wellness promotion and disease prevention across diverse populations. This heritage emphasizes the importance of accessible, accurate health knowledge to support informed decision-making by patients and healthcare providers alike. As this informational framework evolves, attention naturally shifts toward specific therapeutic interventions and their associated risk profiles. One such area of focus involves the relationship between pharmaceutical exposures and adverse health outcomes. In particular, the transition from general health education to occupational exposure concern becomes relevant when examining the clinical use of bisphosphonate medications. These agents, commonly prescribed for bone density management, have been linked to rare but serious complications in certain patient populations. The pivot from broad health science principles to targeted exposure risk assessment requires careful consideration of how therapeutic benefits balance against potential harms. This transition acknowledges that while general health information provides essential context, specific clinical scenarios demand more focused analysis. The occupational exposure concern emerges as a natural extension of this progression, recognizing that healthcare professionals and patients alike must navigate complex risk-benefit decisions in real-world treatment settings.

Understanding Fosamax and Its Link to Osteonecrosis of the Jaw

Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its mechanism involves increasing bone mass and reducing fracture incidence, including hip and spine fractures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, a known adverse effect associated with bisphosphonates, including Fosamax, is osteonecrosis of the jaw (ONJ), a condition characterized by exposed, non-healing bone in the jaw that can occur spontaneously or following dental procedures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Clinical presentation and diagnosis of ONJ typically involve delayed healing after tooth extraction, local infection, or spontaneous bone exposure. The condition is generally associated with invasive dental procedures, such as tooth extraction, dental implants, or boney surgery, as well as local infection (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Known risk factors include diagnosis of cancer, concomitant therapies like chemotherapy, corticosteroids, or angiogenesis inhibitors, poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, or ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with longer duration of bisphosphonate exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Mechanistic Pathways and Temporal Relationship

Mechanistic pathways linking Fosamax to ONJ are not fully elucidated, but research suggests that jawbone-specific responses to bisphosphonates may play a role. A multiscale characterization of jawbone provides comprehensive information that can help understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). This indicates that the unique biology of the jawbone may contribute to its vulnerability to bisphosphonate-induced harm. Regarding the timeline between exposure and documented harm, the time to onset of symptoms after starting Fosamax can vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the drug, but a subset experienced recurrence when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Population-Level Risk and Duration of Use

Population-level data further clarify the risk. Among female patients treated for osteoporosis, ONJ risk was threefold higher after 2-3 years of treatment and eightfold higher after 10 years compared with past use (https://pubmed.ncbi.nlm.nih.gov/39400702/). Absolute risks remained low, approximately 0.05% after 5 years, and diminished after discontinuation (https://pubmed.ncbi.nlm.nih.gov/39400702/). This study, conducted among cancer-free female patients aged 40-89 in the United Kingdom Clinical Practice Research Datalink, underscores that while the relative risk increases with duration, the absolute risk is small (https://pubmed.ncbi.nlm.nih.gov/39400702/).

Adequacy of Warnings and Causation Considerations

Adequacy of warnings regarding Fosamax and ONJ is addressed in the prescribing information. The label explicitly states that ONJ has been reported in patients taking bisphosphonates, including Fosamax, and lists known risk factors (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56; https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The label also advises that discontinuation of bisphosphonate treatment may reduce risk for patients requiring invasive dental procedures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the label notes that in placebo-controlled clinical studies, the percentages of patients with symptoms were similar in the Fosamax and placebo groups, which may complicate risk communication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Causation-related considerations for affected patients involve establishing a temporal relationship between Fosamax use and ONJ onset, excluding other causes such as cancer or concurrent medications, and assessing duration of exposure. The label indicates that symptoms can appear from one day to several months after starting the drug, and that recurrence upon rechallenge supports causation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The risk increases with longer use, as shown by the eightfold higher risk after 10 years (https://pubmed.ncbi.nlm.nih.gov/39400702/). For patients who develop ONJ, discontinuation of Fosamax is recommended if severe symptoms develop, and most patients experience relief after stopping (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In summary, evidence from clinical studies and population data supports a causal association between Fosamax use and ONJ, with risk increasing with duration of exposure. The prescribing information provides warnings about this risk, though the absolute risk remains low. Patients and clinicians should weigh the benefits of fracture reduction against the rare but serious risk of ONJ, particularly with long-term use.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.

Frequently Asked Questions

What is Fosamax and how does it work?

Fosamax (alendronate) is a bisphosphonate medication approved for treating and preventing osteoporosis, increasing bone mass in men with osteoporosis, treating glucocorticoid-induced osteoporosis, and treating Paget's disease of bone. It works by increasing bone mass and reducing fracture incidence, including hip and spine fractures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What is osteonecrosis of the jaw (ONJ) and how is it linked to Fosamax?

Osteonecrosis of the jaw (ONJ) is a condition characterized by exposed, non-healing bone in the jaw that can occur spontaneously or after dental procedures. It is a known adverse effect of bisphosphonates like Fosamax. Risk factors include invasive dental procedures, cancer, chemotherapy, corticosteroids, poor oral hygiene, and longer duration of bisphosphonate use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56; https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

How common is ONJ in patients taking Fosamax?

The absolute risk of ONJ is low. In a study of female osteoporosis patients, the risk was approximately 0.05% after 5 years of treatment. However, the relative risk increases with longer use: threefold higher after 2-3 years and eightfold higher after 10 years compared to past use (https://pubmed.ncbi.nlm.nih.gov/39400702/).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.